ReviewNature biotechnology2025
Engineering B cells to treat and study human disease.
Review in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.bioRxiv : the preprint server for biology · 2026Article
- Modeling human B cell development with pluripotent stem cells.bioRxiv : the preprint server for biology · 2026Article
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- Toward CAR-B cells for HIV-1 therapy.Molecular therapy. Methods & clinical development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Modern cell therapies are designed to harness natural biology to treat a range of complex diseases. The field of immunology has shown that B cells exhibit multiple unique features, including a natural propensity to interact with and regulate other immune cells, a high capacity to produce proteins, and a long cellular lifespan, which are being creatively applied in engineered B cell (eB cell) therapies. In recent years, advances in genome editing technologies and animal modeling have facilitated rapid progress in our ability to study eB cells and execute proof-of-concept studies, thus enabling the first clinical trials of eB cell therapies. In this review, we provide an overview of recent developments in eB cell therapies, including early clinical studies. We discuss challenges to clinical implementation, and promising directions for leveraging B cell biology in future applications for cancer and chronic disease.
Indexed as
Identifiers
40764821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.